Articles By Wayne Koberstein, Executive Editor

From Disney’s World To DC — City Hopping For ENDO & AACR
From Disney’s World To DC — City Hopping For ENDO & AACR Orlando, the city of warmth and happiness by design, hosted the Endocrine Society’s annual ENDO event this year, overlapping the Washington, DC-hosted AACR, the yearly confab by the American Association for Cancer Research, by several days. I was determined to visit both shows.  Continue Reading...
  • Leading Business With Science: Geert Cauwenbergh of RXi
    Leading Business With Science: Geert Cauwenbergh of RXi

    Geert Cauwenbergh now can look back at his almost four decades in the industry — from his formative years working with Paul Janssen building a small company into a global phenomenon, to his later years as a startup entrepreneur with RXi — and reflect on how most of it has turned upon a snap decision.

  • Companies To Watch: Aridis Pharmaceuticals
    Companies To Watch: Aridis Pharmaceuticals

    An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.

  • Preventing Delayed Cerebral Ischemia (DCI): Edge Therapeutics
    Preventing Delayed Cerebral Ischemia (DCI): Edge Therapeutics

    In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.

  • Grünenthal’s Plan To Grow Globally & Expand Its Pipeline
    Grünenthal’s Plan To Grow Globally & Expand Its Pipeline

    Board Chairman & CEO Gabriel Baertschi talks about why the private, European-based company is widening its base with new approaches and technologies for treating pain and, now, related conditions.

  • Contrasts & Creativity at BIO CEO & Investor 2017
    Contrasts & Creativity at BIO CEO & Investor 2017

    At BIO CEO many of the companies on my radar this year are in the metabolic/endocrinology area, over which diabetes has long reigned. But the area is now expanding noticeably into other spheres such as neurodegeneration and cardiovascular. As Albion Fitzgerald, chairman of CohBar, says “During the next 15 years, there will be five times as many deaths from noncommunicable diseases as from the old historic communicable diseases, and most noncommunicable diseases are metabolic diseases.”

  • A Progress Report On The 2016 Companies To Watch
    A Progress Report On The 2016 Companies To Watch

    There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.

  • The Enterprisers: CohBar - Producing Mitochondria Medicine
    The Enterprisers: CohBar - Producing Mitochondria Medicine

    Why shouldn’t our mitochondria want us to live long, prospering in good health? Why shouldn’t they — as symbiotic microbes turned cellular organelles with their own mini-genomes — carry genes that help ensure our healthful survival?

  • The Wider Net — JPM Healthcare Conference 2017 In SF
    The Wider Net — JPM Healthcare Conference 2017 In SF

    At the JPM conference, I spend the bulk of my time meeting with a string of companies, but as various as they are, they all share the common challenge of risk and uncertainty in the development of human therapeutics. For us in the press, it can be tempting to toss companies into easy categories such as size, stage of research, market cap  - but then, it’s fun and interesting to let the patterns among the companies emerge spontaneously as each one falls into context. The following describes just a couple of examples.

  • Companies To Watch: Ritter Pharmaceuticals
    Companies To Watch: Ritter Pharmaceuticals

    On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance

  • Janssen Immunology — Science & Market Drivers
    Janssen Immunology — Science & Market Drivers

    In this exclusive with Sue Dillon, Ph.D., head of Janssen Immunology, she talks candidly about topics such as how the company marries the precommercial and commercial functions.

  • Night Of Light: California Life Science Association (CLSA)
    Night Of Light: California Life Science Association (CLSA)

    Because I live only a day-trip away from San Francisco, it is convenient for me to travel there for industry events — a trek always accompanied by reflective reveries for the hometown of my film-student days. So, for the third time since June, and with another week scheduled for early January, I am once again city-bound, leaving home mid-day and getting into my hotel in plenty of time to make the 5:30 PM reception for the annual Pantheon Awards dinner, held by the California Life Science Association (CLSA).

  • Company Leaders Tackle The New Year’s Toughest Macro Challenges
    Company Leaders Tackle The New Year’s Toughest Macro Challenges

    We posed some difficult questions to biopharma-company leaders on tough political, economic, and business challenges — those likely to become even tougher for the industry in 2017. The bravest among the invited answered our queries with thoughtful responses regarding thorny issues such as Brexit and the U.S. election, drug pricing and reimbursement, new life science business models, and the industry’s technological future.

  • BIO Shines In San Francisco
    BIO Shines In San Francisco

    This year, the BIO Investor Forum (#BIF16) in San Francisco enjoyed its largest turnout ever, basked in the light and warmth of a dynamic industry that may not solve all of the world’s problems, but shines upon us, a salubrious star. Will the industry’s star shine upon everyone, or leave most of humanity in the shadows?

  • Why Now Is A Pivotal Time For Rare-Disease Pharma Catabasis
    Why Now Is A Pivotal Time For Rare-Disease Pharma Catabasis

    There is an obvious, timely issue with Catabasis that deserves observation but should not eclipse the whole of the company — its Phase 2 candidate for treating DMD.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.